Ganirelix
From Wikipedia, the free encyclopedia
 |
|
|
Ganirelix
|
|
| Systematic (IUPAC) name | |
| N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3- pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N9,N10-diethyl-D-homoarginyl-L-leucyl-N9,N10-diethyl-L- homoarginyl-L-prolyl-D-alanylamide acetate | |
| Identifiers | |
| CAS number | 129311-55-3 (diacetate) |
| ATC code | H01 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | ? |
| Mol. mass | 1570.4 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 91.1% |
| Protein binding | 81.9% |
| Metabolism | ? |
| Half life | 12.8 hours |
| Excretion | Faecal / Renal (approx. 75%/22%) |
| Therapeutic considerations | |
| Pregnancy cat. |
X(US) |
| Legal status | |
| Routes | Subcutaneous injection |
Ganirelix acetate (or diacetate) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in assisted reproduction to control ovulation. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. It is administered as a daily subcutaneous injection.
Ganirelix is marketed by Organon International as Antagon.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
